




PHARMACEUTICAL 2022

Acer Therapeutics Inc.
Rank 388 of 466





PHARMACEUTICAL 2022

Acer Therapeutics Inc.
Rank 388 of 466



The relative strengths and weaknesses of Acer Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acer Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Acer Therapeutics Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is -49%, being 127% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	28,089
Cost of Goods Sold	0
Intangible Assets	7,647
Liabilities, Current	29,110
Liabilities, Non-Current	209
Other Assets	407
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	8,661
Other Net Income	574
Other Revenues	1,260
Property and Equipment	114
Research and Development	6,508
Selling, General and Administrative Expense	10,700

Output Variable	Value in 1000 USD
Assets	36,257
Liabilities	37,981
Expenses	17,208
Revenues	1,260
Stockholders Equity	-1,724
Net Income	-15,374
Comprehensive Net Income	-15,374
Economic Capital Ratio	-49%